Heart最新文献

{"title":"Determinants of medication adherence in patients with acute coronary syndrome: a secondary analysis of a randomised clinical trial.","authors":"Richard Kha, Haeri Min, Simone Marschner, Shehane Mahendran, Aravinda Thiagalingam, Rohan Poulter, Julie Redfern, David Brieger, Peter L Thompson, Graham S Hillis, Nicholas Collins, Pratap Shetty, Michele McGrady, Christian Hamilton-Craig, Nadarajah Kangaharan, John Atherton, Andrew Maiorana, Harry Klimis, Craig Juergens, Clara K Chow","doi":"10.1136/heartjnl-2024-325144","DOIUrl":"10.1136/heartjnl-2024-325144","url":null,"abstract":"<p><strong>Background: </strong>Coronary heart disease (CHD) remains a leading cause of mortality and disability worldwide. Approximately half of the patients who have had a prior hospital admission for CHD will have a recurrent coronary event, with the majority of these occurring within 12 months. Despite well-established evidence-based therapies, medication non-adherence is highly prevalent and reasons for medication non-adherence are poorly understood. This study evaluates factors influencing adherence to secondary prevention medications in people with acute coronary syndrome (ACS).</p><p><strong>Methods: </strong>We performed a secondary analysis of TEXT messages to improve MEDication adherence and Secondary prevention after ACS (TEXTMEDS), a single-blind randomised clinical trial of 1424 patients with ACS from 18 hospitals across Australia. The primary outcome was self-reported medication adherence to each of up to five classes of guideline-recommended cardioprotective medications indicated for secondary prevention after ACS. Patients were followed up at 6-month and 12-month time points and were defined as adherent if at both time points, the proportion of indicated medications taken was >80% (>24/30 days in the preceding 1 month) for all five classes if not otherwise contraindicated. Logistic regression analysis and the Least Absolute Shrinkage and Selection Operator regularisation technique were used to assess the effect of sociodemographic and clinical factors on medication adherence.</p><p><strong>Results: </strong>The analyses included 1379 participants with complete adherence data (mean age 58.5±10.7 years; 1095 (79.4%) men). The following variables were associated with adherence to cardiovascular medications at both 6 and 12 months: greater number of total medications taken (OR: 1.33; 95% CI: 1.25 to 1.42) and attending a cardiac rehabilitation programme (1.47; 95% CI: 1.17 to 1.86). In contrast, female sex (0.67; 95% CI: 0.50 to 0.90) and physical disability (0.43; 95% CI: 0.23 to 0.77) were associated with lower likelihood of medication adherence.</p><p><strong>Conclusions: </strong>Sociodemographic and clinical factors may influence medication adherence. Greater awareness, discussion and monitoring of these factors during patient follow-up may help improve medication adherence.</p><p><strong>Trial registration number: </strong>Australian New Zealand Clinical Trials Registry; URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364448; registration number: ACTRN12613000793718.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":"462-470"},"PeriodicalIF":5.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanical circulatory support for patients with infarct-related cardiogenic shock: a state-of-the-art review.","authors":"Jacob Eifer Moller, Holger Thiele, Uwe Zeymer, Alastair Proudfoot, Christian Hassager","doi":"10.1136/heartjnl-2024-324883","DOIUrl":"10.1136/heartjnl-2024-324883","url":null,"abstract":"<p><p>Acute myocardial infarction-related cardiogenic shock (AMI-CS) is a severe, life-threatening condition characterised by inadequate tissue perfusion due to the heart's inability to pump blood effectively. The pathophysiology of AMI-CS usually arises from the sudden loss of myocardial contractility, leading to a decrease in cardiac output and systemic hypoperfusion. In approximately 90% of AMI-CS cases, the left ventricle is the primary site of dysfunction.Despite early recognition and the implementation of strategies such as primary percutaneous coronary intervention, the mortality rate associated with AMI-CS remains alarmingly high, reflecting significant unmet clinical needs. A major challenge lies in identifying the optimal patient population for mechanical circulatory support (MCS) devices, as these interventions are costly and can lead to serious complications.This review provides a comprehensive overview of the pathophysiological mechanisms underlying AMI-CS, explores the current range of MCS devices available and offers an in-depth discussion on the balance of benefits and risks associated with these devices. By highlighting key evidence from recent studies, we aim to shed light on the clinical decision-making process and improve outcomes in this high-risk patient population.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":"445-453"},"PeriodicalIF":5.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of cardiac sarcoidosis and arrhythmogenic cardiomyopathy-associated genetic variants: a multicentre case-control study.","authors":"Valentina Alice Rossi, Matteo Palazzini, Enrico Ammirati, Alessio Gasperetti, Martin Grubler, Corinna Brunckhorst, Robert Manka, Andreas Giannopoulos, Felix C Tanner, Argelia Medeiros-Domingo, Piero Gentile, Manuela Bramerio, Dörthe Schmidt, Claudio Tondo, Andreas J Flammer, Frank Ruschitzka, Firat Duru, Ardan Muammer Saguner","doi":"10.1136/heartjnl-2024-324525","DOIUrl":"10.1136/heartjnl-2024-324525","url":null,"abstract":"<p><strong>Background: </strong>Cardiac sarcoidosis (CS) is a chronic inflammatory disease characterised by non-caseating granulomas, while arrhythmogenic cardiomyopathy (ACM) is a genetic condition mainly affecting desmosomal proteins. The coexistence of CS and genetic variants associated with ACM is not well understood, creating challenges in diagnosis and management. This study aimed to describe the clinical, imaging and genetic features of patients with both conditions.</p><p><strong>Methods: </strong>This was a multicentre retrospective case-control study involving three groups of patients: those with biopsy-proven CS and pathogenic or likely pathogenic genetic variants linked to ACM (n=5); patients with genetic variants but no CS (n=5); and patients with CS without genetic variants (n=5). Clinical data, including symptoms, electrocardiographic findings and imaging results from echocardiography, cardiac magnetic resonance and positron-emission tomography, were analysed.</p><p><strong>Results: </strong>Patients with CS and genetic variants were more likely to exhibit atrioventricular block (100%), PR prolongation (204 ms vs 160 ms) and paroxysmal atrial fibrillation (80%) compared with those with genetic variants alone (0% for both). Imaging findings showed a higher prevalence of septal involvement in patients with both conditions (80%) than in those with genetic variants alone (20%). No significant differences were observed between patients with CS and genetic variants and those with CS without genetic variants. The genetic variants identified included variants in PKP2 (40%), DSG2 (20%), DSP (20%) and TTN (20%).</p><p><strong>Conclusions: </strong>The coexistence of CS and ACM-associated genetic variants is associated with distinct clinical features, including PR prolongation, AVB1°, septal involvement and paroxysmal atrial fibrillation. These findings emphasise the need to evaluate for CS in individuals with ACM and associated genetic variants who present with conduction abnormalities or septal involvement, guiding tailored diagnostic and therapeutic strategies.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":"480-486"},"PeriodicalIF":5.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention.","authors":"Cheng Wang, Nadira Hamid, Vinayak Bapat, Joao L Cavalcante, John R Lesser, Evan Walser-Kuntz, Larissa Stanberry, Maurice Enriquez-Sarano, Paul Sorajja","doi":"10.1136/heartjnl-2024-325194","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-325194","url":null,"abstract":"<p><strong>Background: </strong>Tricuspid regurgitation (TR) progression following left-sided valvular heart disease (VHD) correction is a critical clinical concern. This study aimed to determine the incidence, predictors and outcomes of TR progression in a contemporary cohort.</p><p><strong>Methods: </strong>We analysed 1644 patients (mean age 73 years, 62% men) without severe TR who underwent surgical or transcatheter treatment for aortic or mitral disease between 2014 and 2018. TR progression was defined as an increase in TR grade to moderate or severe on follow-up echocardiography.</p><p><strong>Results: </strong>At 5 years, TR progression incidence was 12.0% (95% CI 10.5% to 13.7%). Baseline factors associated with TR progression included older age, female sex, atrial fibrillation, prior pacemaker implantation and larger tricuspid annular diameter (TAD). The relationship between TAD and TR progression was linear (HR 1.08; 95% CI 1.04 to 1.11; p<0.001), with sex differences mitigated by indexing TAD to body surface area. TR progression was associated with increased all-cause mortality (adjusted HR 2.77; 95% CI 2.16 to 3.56; p<0.001) and a combined endpoint of death or heart failure hospitalisation (adjusted HR 2.91; 95% CI 2.21 to 3.82; p<0.001).</p><p><strong>Conclusions: </strong>TR progression is common after left-sided VHD correction and is associated with adverse outcomes. Indexing TAD to body surface area mitigates sex differences in risk assessment. These findings suggest that lower thresholds for prophylactic tricuspid intervention may be warranted in high-risk patients.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk and management of cardiac disease in kidney and liver transplant recipients.","authors":"Gautam R Shroff, Mina M Benjamin, Janani Rangaswami, Krista L Lentine","doi":"10.1136/heartjnl-2024-324796","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-324796","url":null,"abstract":"<p><p>Organ transplantation is the treatment of choice for individuals with kidney failure requiring kidney replacement therapy, as well as for those with end-stage liver disease. Despite the significant reduction in long-term morbidity and mortality with transplantation, kidney and liver allograft recipients remain at high risk for cardiovascular disease (CVD) and premature death from cardiovascular causes. This heightened risk is represented across all phenotypes of CVD, including coronary heart disease, heart failure, arrhythmias, valvulopathies and pulmonary hypertension. Pre-existing vascular risk factors for CVD, coupled with superimposed cardiovascular-kidney-metabolic derangements after transplantation, driven at least in part by post-transplant weight gain, immunosuppressive therapies and de novo risk factors such as dyslipidaemia and diabetes, coalesce to increase total CVD risk. In this review, we summarise pathophysiological considerations for both the short- and long-term increase in CVD risk following kidney/liver transplantation. We review the different phenotypes of CVD, with unique considerations for post-transplant care in this patient population. Finally, we highlight the need for awareness about long-term CVD risk and a multidisciplinary approach to managing organ-specific CVD risk in kidney and liver transplant patients.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulation in patients with low-burden atrial fibrillation: new evidence focussing on device-detected AF.","authors":"Nina Becher, Andreas Metzner, Paulus Kirchhof","doi":"10.1136/heartjnl-2024-324848","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-324848","url":null,"abstract":"<p><p>Stroke, one of the most severe complications of atrial fibrillation (AF), can be prevented by oral anticoagulants in patients with ECG-documented AF and clinical stroke risk factors. Recent controlled trials suggest that reducing the burden of AF, that is, the time spent in AF, can reduce the risk of stroke. Furthermore, stroke rate was slightly lower than anticipated in controlled trials of anticoagulation in screening-detected AF, and substantially lower than expected in patients with device-detected atrial fibrillation (DDAF) and after AF ablation. These data suggest that AF burden modulates the risk of stroke in patients with AF. Based on their high AF burden in observational datasets, anticoagulation remains the default therapy in patients with ECG-documented AF. However, AF burden reduction using rhythm-control therapies emerges as a new treatment strategy for stroke prevention, and there may be a group of patients with such a low burden of AF, for example, patients with DDAF, that the risks of current anticoagulation therapies outweigh their stroke-preventing effects. Patients with DDAF in the absence of ECG-documented AF and without vascular disease appear to be at low risk of thromboembolic events. In patients with DDAF, shared decision-making that considers the presence of vascular disease, potentially the burden of AF if it is very high, and patient preferences currently emerges as good clinical care. More data are needed to robustly define the complex relations between AF burden, phenotypes and stroke risk.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study.","authors":"Rory Maclean, Yang Chen, R Thomas Lumbers, Anoop Dinesh Shah","doi":"10.1136/heartjnl-2024-325132","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-325132","url":null,"abstract":"<p><strong>Background and aims: </strong>Mineralocorticoid receptor antagonists (MRAs) reduce mortality and hospitalisation in heart failure with reduced ejection fraction (HFrEF) but are underused, despite recommendation in key guidelines. Identifying the factors contributing to underuse and addressing adherence are key components of a learning health system. We aimed to evaluate MRA prescription in people with HFrEF who would benefit, based on the UK National Institute for Health and Care Excellence (NICE) HFrEF guideline.</p><p><strong>Methods: </strong>We used clinical code lists to identify people with HFrEF in primary care electronic health record (EHR) data from The Health Improvement Network database. For each calendar year 2014-2020, we identified individuals who met the NICE guideline criteria for MRA therapy. We fitted mixed effects logistic regression models to determine the factors contributing to MRA prescription.</p><p><strong>Results: </strong>Among 24 135 people with HFrEF studied between 2014 and 2020, 12 150 person-years were eligible for MRA treatment. The MRA prescription rate increased from 41% to 55%. MRA prescription was inversely associated with age (OR per 1 SD, 95% CI) (0.02 (0.01, 0.03)), increasing glomerular filtration rate (0.37 (0.25, 0.55)), hypertension (0.21 (0.40, 0.78)) and prescription of antihypertensives (0.03 (0.02, 0.07)). MRA prescription was associated with male gender (6.31 (3.20, 12.4)), dilated cardiomyopathy (25.9 (7.48, 89.4)), calendar year (2.17 (1.85, 2.54) per year after study start) and prescription of sacubitril/valsartan (214 (56, 823)).</p><p><strong>Conclusions: </strong>MRAs are underused in people with HFrEF in the UK. Although prescribing increased between 2014 and 2020, half of the cohort still did not receive the therapy. Older age, gender, comorbidities and co-prescriptions were linked to MRA underuse. Understanding the factors contributing to underprescribing at a population level should be used to inform quality improvement strategies.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional and national epidemiology of myocarditis: health inequalities, risk factors and forecasted burden based on the Global Burden of Disease Study 2021.","authors":"Changjun Li, Kun Xu, Aijia Du, Ningning Fu, Zhaolong Xu, Qinghua Chang","doi":"10.1136/heartjnl-2024-325523","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-325523","url":null,"abstract":"<p><strong>Background: </strong>Myocarditis is a global epidemic that causes various medical conditions associated with an increased incidence and death numbers. This study aimed to investigate the trends in myocarditis-associated incidence, mortality, and disability-adjusted life-years (DALYs) with health inequalities, risk factors, and predict the disease burden, thereby mitigating the health hazards of myocarditis.</p><p><strong>Methods: </strong>This was a modelling study that used data from the Global Burden of Diseases 2021, from which myocarditis was included in the analysis. Incidence, death, DALYs, age-standardised incidence rate (ASIR), age-standardised mortality rate (ASMR), age-standardised DALYs rate (ASDR), cases change, corresponding estimated annual percentage change (EAPC), Slope Inequality of Index (SII) and Concentration Index were analysed.</p><p><strong>Results: </strong>From 1990 to 2021, incidence and death cases increased by 66.88% and 45.94%, respectively. The myocarditis-associated incidence and death cases increased in all five sociodemographic index (SDI) regions. Among the five SDI regions, the High SDI region had the highest myocarditis-associated ASIR with the least ASMR and ASDR in 2021. Regionally, Central Asia had the largest increase in EAPC of ASIR, ASMR and ASDR. Among 204 countries, Japan had the highest ASIR in 2021 and Romania had the highest ASMR and ASDR. Between 1990 and 2021, the SII and Concentration Index for DALYs have shown declining trends. The extreme temperatures were major contributors to the burden of myocarditis during 1990-2021. The projections suggested that the myocarditis-related global number of new cases and death would increase over the next 15 years. There may be upward trends in people of 15+of incidence number and 40+of death and DALYs number.</p><p><strong>Conclusions: </strong>Myocarditis is an increasing global health challenge with rising incidence and death. Management of extreme temperatures remains a major challenge. The number of incidence, death and DALYs in different age groups would continue to grow over the next 15 years. Therefore, measures should be taken to target risk factors and high-risk groups.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving insights into VEGFI cardiotoxicity: past challenges, present findings and future opportunities.","authors":"Kenya Kusunose","doi":"10.1136/heartjnl-2025-326107","DOIUrl":"https://doi.org/10.1136/heartjnl-2025-326107","url":null,"abstract":"","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection.","authors":"Christopher J Love, Joshua Lampert, David Huneycutt, Dan L Musat, Mahek Shah, Jorge E Silva Enciso, Bryan Doherty, James L Gentry, Michael D Kwan, Ethan C Carter, Vivek Y Reddy","doi":"10.1136/heartjnl-2024-325608","DOIUrl":"https://doi.org/10.1136/heartjnl-2024-325608","url":null,"abstract":"<p><strong>Background: </strong>Hypertrophic cardiomyopathy (HCM) is often underdiagnosed. Artificial intelligence (AI)-based notification of HCM suspicion on a 12-lead ECG has been proposed to assist patient identification and evaluation. However, there has been no study to date to assess clinical implementation of this approach.</p><p><strong>Methods: </strong>In an open-label, multicentre prospective cohort study, Viz HCM (Viz.ai)-an AI-ECG software alerting of suspected HCM-was implemented at five healthcare systems between January and December 2023 to identify patients >18 years of age without prior HCM diagnosis. The coprimary endpoints were the percentage of HCM-suspected cases viewed by users and the types of follow-up actions. Additional outcome measures included the time to follow-up, demographic characteristics of enrolled patients and follow-up outcomes.</p><p><strong>Results: </strong>Out of 145 848 patients screened with algorithm-compliant ECGs, 4348 (3%) were alerted for suspected HCM. Users viewed 69% (3017/4348) of AI-suspected HCM cases. 217 patients met the study criteria and were enrolled with broad representation across racial and ethnic groups-including 23% Black, 9% Asian and 12% Hispanic or Latino. Of the enrolled patients, 182 (84%) had an indication for a total of 243 follow-up actions. The median (interquartile) time from ECG to diagnostic imaging indicating HCM was 7.5 (1.0-37.2) days. From the 217 enrolled patients, 17 (7.8%) were newly diagnosed with HCM-8 inpatient and 9 outpatient. During the study, deployment of an optimised algorithm operating point helped reduce the alert percentage of algorithm-screened patients from 4.4% (2097/47868) to 2.3% (2251/97980), p<0.0001, with no difference in the enrolment rate by alerts reviewed.</p><p><strong>Conclusion: </strong>An AI-based ECG device for HCM can be implemented successfully in a variety of clinical workflows to help identify new patients with HCM. Future study is warranted to assess scalability and comparisons to standard of care.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}